Tiziana Executive Chairman Raises Stake to 34.93%
Tiziana Life Sciences’ Executive Chairman Gabriele Cerrone has quietly increased his stake to 34.93% via Panetta Partners, purchasing 42,357 shares at $0.99, signaling strong insider confidence in the clinical-stage biotech’s lead asset intranasal foralumab. The move could bolster governance, financing, and partnership prospects as the company advances its MS-focused immunomodulation programs.